As filed with
the Securities and Exchange Commission on August 14, 2017
Registration
No. 333 -219175
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
AMENDMENT NO.
1
TO
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES
ACT OF 1933
MAGNEGAS
CORPORATION
(Exact name of registrant
as specified in its charter)
Delaware
|
26-0250418
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification Number)
|
11885 44
th
Street North
Clearwater, Florida
33762
(727) 934-3448
(Address, Including
Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
Tyler B. Wilson,
Esq.
General Counsel
11885 44
th
Street North
Clearwater, Florida
33762
(727) 934-3448
(Name, Address, Including
Zip Code, and Telephone Number, Including Area Code, of Agent for Service)
Copy to:
Thomas Levato, Esq.
Goodwin Procter
LLP
The New York Times
Building
620 Eighth Avenue
New York, NY 10018
(212) 459-7256
Approximate
date of commencement of proposed sale to the public
: From time to time after this registration statement becomes effective.
If
the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please
check the following box.
¨
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check
the following box.
x
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check
the following box and list the Securities Act registration statement number of the earlier effective registration statement for
the same offering.
¨
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.
¨
If
this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become
effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.
¨
If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register
additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box.
¨
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
|
¨
|
Accelerated filer
|
¨
|
|
|
|
|
Non-accelerated filer
|
¨
|
Smaller reporting company
|
x
|
|
|
|
|
|
|
Emerging growth company
|
x
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
CALCULATION OF REGISTRATION
FEE
Title
of each class of
securities to be registered
|
|
Amount
to be
Registered(1)
|
|
|
Proposed
Maximum
Offering
Price
Per Share
|
|
|
Proposed
Maximum
Aggregate
Offering Price
|
|
|
Amount of
Registration Fee
|
|
Series
C Convertible Preferred Stock, par value $0.001 per share (3)
|
|
|
75
|
|
|
$
|
1,000
|
(8)
|
|
$
|
75,000
|
(8)
|
|
$
|
8.70
|
|
Common
Stock, par value $0.001 per share, issuable upon conversion of outstanding Series C Convertible Preferred Stock (4)
|
|
|
214,286
|
|
|
|
—
|
|
|
|
—
|
|
|
|
|
(10)
|
Common
Stock, par value $0.001 per share, issuable upon exercise of outstanding Common Stock Warrants (5)
|
|
|
2,916,667
|
|
|
|
$
1.26
|
(2)
|
|
|
$
3,675,000.42
|
(2)
|
|
$
|
425.93
|
|
Common
Stock, par value $0.001 per share, issuable upon exercise of outstanding Placement Agent Warrants (6)
|
|
|
416,667
|
|
|
|
$
1.26
|
(2)
|
|
|
$
525,000.42
|
(2)
|
|
$
|
60.84
|
|
Series
C Convertible Preferred Stock, par value $0.001 per share, issuable upon exercise of outstanding Preferred Stock Warrants (7)
|
|
|
24,925
|
|
|
|
$1,000
|
(8)
|
|
$
|
24,925,000
|
(8)
|
|
$
|
2,888.81
|
|
Common
Stock, par value $0.001 per share, issuable upon conversion of shares of Series C Convertible Preferred Stock which are issuable
upon exercise of outstanding Preferred Stock Warrants (9)
|
|
|
71,214,286
|
|
|
|
—
|
|
|
|
—
|
|
|
|
|
(10)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
$
|
29,200,000.80
|
|
|
|
$
3,384.28
|
(11)
|
|
(1)
|
Represents
shares offered by the selling stockholders. Includes an indeterminable number of additional
shares pursuant to Rule 416 under the Securities Act of 1933, as amended, that may be
issued to prevent dilution from stock splits, stock dividends or similar transactions
that could affect the shares to be offered by selling stockholders.
|
|
(2)
|
Estimated
solely for the purpose of calculating the registration fee in accordance with Rule 457(c) of the Securities Act, based on the
average of the high and low prices of the common stock of the registrant as reported on The NASDAQ Capital Market on July 3, 2017.
|
|
(3)
|
Represents
75 shares of Series C Convertible Preferred Stock issued and outstanding.
|
|
(4)
|
Represents
shares issuable upon conversion of outstanding shares of Series C Convertible Preferred
Stock, with each share of Series C Convertible Preferred Stock having a stated value
of $1,000 per share and an initial conversion price into shares of common stock
of $3.00 per share. The conversion price is variable as provided in the Series
C Convertible Preferred Stock's governing document. The number of shares of
common stock included represents the maximum number of shares of common stock that may
be issuable upon conversion of the Series C Convertible Preferred Stock calculated assuming
a conversion price floor of $0.35 per share.
|
|
(5)
|
Represents
shares issuable upon exercise of outstanding Common Stock Warrants, at a fixed exercise
price of $3.00 per share.
|
|
(6)
|
Represents
shares issuable upon exercise of outstanding Placement Agent Warrants, at a fixed exercise
price of $3.30 per share.
|
|
(7)
|
Represents
shares issuable upon exercise of outstanding Preferred Stock Warrants, at a fixed exercise
price of $900 per share.
|
|
(8)
|
Estimated
solely for purposes of calculating the registration fee pursuant to Rule 457(i) under
the Securities Act.
|
|
(9)
|
Represents
shares issuable upon conversion of shares of Series C Convertible Preferred Stock which
are issuable upon exercise of outstanding Preferred Stock Warrants, with each share of
Series C Convertible Preferred Stock having a stated value of $1,000 per share and an
initial conversion price into shares of common stock of $3.00 per share. The
conversion price is variable as provided in the Series C Convertible Preferred Stock's
governing document. The number of shares of common stock included represents
the maximum number of shares of common stock that may be issuable upon conversion of
the Series C Convertible Preferred Stock calculated assuming a conversion price floor
of $0.35 per share
|
|
(10)
|
No
separate consideration will be received for the shares of common stock issuable upon
conversion of the of Series C Convertible Preferred Stock; therefore, no registration
fee for those shares is required pursuant to Rule 457(i) under the Securities Act.
|
|
(11)
|
A
filing fee of $490.43 was paid by the registrant upon the initial filing of this registration
statement on July 6, 2017. Pursuant to Rule 457(p) under the Securities Act,
the registrant is offsetting the registration fee due under this registration statement
by $2,600, which represents the portion of the registration fee previously paid with
respect to $22,432,500 of securities covered by registration statement on Form S-1 (File
No. 333-219138), which was initially filed on June 30, 2017 and subsequently withdrawn. Accordingly,
the filing fee due in connection with this filing is $293.85.
|
The Registrant
hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant
shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in
accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such
date as the Commission acting pursuant to said Section 8(a), may determine.
The
information in this prospectus is not complete and may be changed. The selling stockholders named in this prospectus may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus
is not an offer to sell these securities and the selling stockholders named in this prospectus are not soliciting offers to buy
these securities in any jurisdiction where the offer or sale is not permitted.
Subject
to completion, dated August 14, 2017
PRELIMINARY PROSPECTUS
MAGNEGAS CORPORATION
75 Shares of
outstanding Series C Convertible Preferred Stock
(and 214,286 shares of Common Stock
issuable upon conversion of the Series C Convertible Preferred Stock)
2,916,667 Shares
of Common Stock issuable upon exercise of outstanding Common Stock Warrants
416,667 Shares
of Common Stock issuable upon exercise of outstanding Placement Agent Warrants
24,925 Shares
of Series C Convertible Preferred Stock issuable upon
exercise of outstanding Preferred Stock Warrants
(and 71,214,286 shares of Common Stock issuable upon conversion of the Series C Convertible Preferred Stock)
This prospectus relates to the resale by
the selling stockholders identified in this prospectus of (i) 75 shares of outstanding Series C Convertible Preferred Stock (and
up to 214,286 shares of common stock that are issuable upon the conversion of the Series C Convertible Preferred Stock), (ii)
up to 2,916,667 shares of common stock that are issuable upon the exercise of outstanding common stock warrants, (iii) up to 416,667
shares of common stock that are issuable upon the exercise of outstanding placement agent warrants, and (iv) up to 24,925 shares
of Series C Convertible Preferred Stock that are issuable upon the exercise of outstanding preferred stock warrants (and up to
71,214,286 shares of common stock that are issuable upon the conversion of the Series C Convertible Preferred Stock that are issuable
upon the exercise of outstanding preferred stock warrants), all of which were issued to the selling stockholders in connection
with a private placement completed on June 15, 2017.
We are not selling any shares of preferred
stock or common stock and will not receive any proceeds from the sale of the shares under this prospectus. Upon the exercise of
the common stock warrants for 2,916,667 shares of our common stock by payment of cash, we will receive the exercise price of the
warrants, which is $3.00 per share, or an aggregate of approximately $8,750,001. Upon the exercise of the placement agent warrants
for 416,667 shares of our common stock by payment of cash, we will receive the exercise price of the warrants, which is $3.30
per share, or an aggregate of approximately $1,375,001. Upon the exercise of the preferred stock warrants for 24,925 shares of
our Series C Convertible Preferred Stock by payment of cash, we will receive the exercise price of the warrants, which is $900
per share, for an aggregate of approximately $22,432,500.
We have agreed to bear all of the expenses
incurred in connection with the registration of these shares. The selling stockholders will pay or assume brokerage commissions
and similar charges, if any, incurred for the sale of shares.
The selling stockholders identified in
this prospectus, or their pledgees, donees, transferees or other successors-in-interest, may offer the shares from time to time
through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately
negotiated prices. For additional information on the methods of sale that may be used by the selling stockholders, see the section
entitled “Plan of Distribution” on page 11 of this prospectus. For a list of the selling stockholders, see the section
entitled “Selling Stockholders” on page 5 of this prospectus.
We may amend or supplement this prospectus
from time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments or
supplements carefully before you make your investment decision.
Our common stock is listed on the NASDAQ
Capital Market under the symbol “MNGA.” On August 9, 2017, the last reported sale price of our common stock on the
NASDAQ Capital Market was $0.46 per share. The Series C Convertible Preferred Stock will not be listed on any national securities
exchange. There is no established public trading market for the Series C Convertible Preferred Stock, and we do not expect a market
to develop.
We are an emerging growth company, as defined
in Section 2(a) of the Securities Act of 1933.
Investing in the securities involves
a high degree of risk. See “Risk Factors” beginning on page 4 of this prospectus and in the documents to be filed
with the Securities and Exchange Commission that are incorporated by reference in this prospectus before making a decision to
purchase our securities.
Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is ,
2017.
TABLE OF CONTENTS
You should rely only on
the information contained in or incorporated by reference into this prospectus. We have not authorized any other person to provide
you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. Neither
we nor the selling stockholders will make an offer to sell these securities in any jurisdiction where the offer or sale is not
permitted.
You should assume that
the information appearing in this prospectus is accurate as of the date on its cover, and that any information incorporated by
reference is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise. Our business,
financial condition, results of operations and prospects may have changed since those dates.
PROSPECTUS SUMMARY
This summary does not
contain all the information that you should consider before investing in our securities. You should carefully read the entire prospectus
and the documents incorporated by reference herein, including “Risk Factors” and the consolidated financial statements
and related notes, before making an investment decision. All references to “we,” “us,” “our,”
and the “company” mean MagneGas Corporation and its subsidiaries.
Our Company
MagneGas Corporation is
a technology company that utilizes a plasma based system for the gasification and sterilization of liquid waste. A byproduct of
our process is a hydrogen based fuel that we sell for metal cutting as an alternative to acetylene, or MagneGas2®. In addition,
we are developing the use of our fuel for co-combustion with hydrocarbon fuels to reduce emissions. We also market, for sale or
licensure, our proprietary plasma arc technology for the processing of liquid waste, or the Plasma Arc Flow® System”.
We have established a retail and distribution platform to sell our fuel for use in the metalworking industries; we have developed
a global network of brokers to sell our system for processing liquid waste and we are testing our fuel through a third party laboratory
for use in the reduction of coal emissions. Additionally, we intend to acquire complementary gas distribution businesses in order
to become a larger distributor of MagneGas2®, other industrial gases and related equipment.
In October of 2014, we
purchased Equipment Sales and Services, Inc., or ESSI, for $3 million cash. ESSI is a full line seller of industrial gases and
equipment for the welding and metal cutting industries. Since acquiring ESSI, we have opened three additional retail locations
and distribute our proprietary MagneGas2® product as well as other gases and welding supplies through ESSI, our wholly owned
subsidiary.
On February 1, 2017, we
formed two wholly owned subsidiaries in the State of Delaware called MagneGas Energy Solutions, LLC and MagneGas Welding Supply,
LLC, respectively.
On March 3, 2017, we formed
three wholly owned subsidiaries in the State of Delaware called MagneGas Real Estate Holdings, LLC, MagneGas IP, LLC and MagneGas
Production, LLC, respectively.
Products
We currently sell three
products: (i) our proprietary fuel, MagneGas2®, for the metal working industry, (ii) a fully portable, all-in-one metal cutting
torch system , used primarily in the firefighting industry, known as MagneTote and (iii) the machines that produce MagneGas2®,
known as Plasma Arc Flow® refineries. In addition, we sell metal cutting fuels and ancillary products through ESSI. While our
original fuel for the metal working industry was known as MagneGas®, we started selling MagneGas2® in July 2014 and stopped
selling MagneGas® in March 2015.
Strategy
We are pursuing three major market segments:
|
·
|
equipment
sales for liquid waste processing; and
|
|
·
|
use
of MagneGas2® for the co-combustion of hydro-carbon fuels to reduce emissions
|
June Private Placement
On June 15, 2017, we closed
a private placement financing, or the June Private Placement, in which we sold shares of Series C Convertible Preferred Stock,
Warrants to Purchase Series C Convertible Preferred Stock and Warrants to Purchase Common Stock, for a total gross purchase price
of up to $25,000,000. At the closing, we issued to the investors a total of 75 shares of Series C Convertible Preferred Stock at
a purchase price of $900 per share. The Series C Convertible Preferred Stock has an initial conversion price equal to $3.00 per
share. We also issued to the investors warrants to purchase up to 24,925 shares of Series C Convertible Preferred Stock at an exercise
price of $900 per share. The aggregate of 25,000 shares of Series C Convertible Preferred Stock will be initially convertible into
an aggregate of 8,333,334 shares of common stock. We also issued to the investors warrants to purchase up to 2,916,667 shares of
common stock at an exercise price of $3.00 per share. Finally, we issued to the placement agent for the June Private Placement,
as partial compensation, placement agent warrants to purchase up to 416,667 shares of common stock at an exercise price of $3.30
per share.
July Registered Direct Offering
On July 27, 2017, we
closed a registered direct financing, or the July Registered Direct Offering, in which we sold 150,000 shares of common stock
at a purchase price of $1.00 per share, for gross proceeds of $150,000. We also issued to the investors Warrants to Purchase Series
D Convertible Preferred Stock, which will be exercisable for a total of 694,422 shares of Series D Convertible Preferred Stock
at an exercise price of $1.00 per share. The Series D Convertible Preferred Stock have an initial conversion price of $1.00 and
will be initially convertible into an aggregate of 694,422 shares of common stock. The July Registered Direct Offering was made
pursuant to a prospectus supplement and accompanying base prospectus relating to the Company’s effective shelf registration
statement on Form S-3 (File No. 333-207928).
Reverse Stock Split
On May 19, 2017, we completed
a one-for-ten reverse stock split of our issued and outstanding shares of common stock, par value $0.001 per share, which we refer
to as the Reverse Stock Split. At that time, every ten shares of our issued and outstanding common stock were automatically combined
into one issued and outstanding share of our common stock. No fractional shares were issued in connection with the Reverse Stock
Split. All historical share and share-related information presented in this prospectus gives effect to the Reverse Stock Split.
Corporate Information
MagneGas Corporation was
organized under the laws of the State of Delaware on December 9, 2005. Our principal office is located at 11885 44
th
Street North, Clearwater, Florida 33762 and its telephone number is (727) 934-3448.
We file Annual Reports
on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other items with the Securities and Exchange Commission,
or the SEC. We provide access free of charge to all of these SEC filings, as soon as reasonably practicable after filing, on our
internet site located at
www.magnegas.com
. The information on our website is not incorporated by reference into this prospectus
and should not be considered to be part of this prospectus.
We
qualify as an "emerging growth company" as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act.
As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise
applicable generally to public companies, including:
|
•
|
reduced
disclosure about our executive compensation arrangements;
|
|
•
|
exemption
from the requirements to hold non-binding advisory votes on executive compensation and golden parachute payments; and
|
|
•
|
exemption
from the auditor attestation requirement in the assessment of our internal control over financial reporting.
|
We
may take advantage of these exemptions up until such time that we are no longer an emerging growth company. We may choose to take
advantage of some, but not all, of the available exemptions. We have taken advantage of certain reduced reporting obligations in
this prospectus. Accordingly, the information contained herein may be different than the information you receive from other public
companies in which you hold stock.
In
addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying
with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards
until those standards would otherwise apply to private companies. We have not elected to avail ourselves of this exemption and,
therefore, while we are an emerging growth company we will be subject to new or revised accounting standards at the same time that
they become applicable to other public companies that are not emerging growth companies.
The Offering
Securities offered by
the selling stockholders
|
|
(i)
75 shares of outstanding Series C Convertible Preferred Stock (and 214,286 shares of common stock issuable upon conversion
of the Series C Convertible Preferred Stock), (ii) up to 2,916,667 shares of common stock that are issuable upon the exercise
of outstanding common stock warrants, (iii) up to 416,667 shares of common stock that are issuable upon the exercise of outstanding
placement agent warrants, and (iv) 24,925 shares of Series C Convertible Preferred Stock that are issuable upon the exercise
of outstanding preferred stock warrants (and up to 71,214,286 shares of common stock that are issuable upon the conversion
of the Series C Convertible Preferred Stock that are issuable upon the exercise of outstanding preferred stock warrants),
|
|
|
|
Common stock outstanding
|
|
11,361,309 shares
|
|
|
|
Use of proceeds
|
|
We will not receive
any proceeds from the sale of shares in this offering, but we will receive the exercise price of the common stock warrants
at the time of exercise, which is $3.00 per share, the placement agent warrants at the time of exercise, which is $3.30 per
share, and the preferred stock warrants at the time of exercise, which is $900 per share.
|
|
|
|
Risk Factors
|
|
You should read the “Risk Factors” section of this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.
|
|
|
|
NASDAQ Capital Market symbol
|
|
“MNGA.” The
shares of Series C Convertible Preferred Stock are not currently, and will not be in the future, listed on any national securities
exchange. There is no established public trading market for the Series C Convertible Preferred Stock, and we do not expect
a market to develop.
|
The number of shares
of our common stock outstanding is based on 11,361,309 shares of our common stock outstanding as of August 9, 2017 and excludes
the following (in each case, as of August 9, 2017):
|
•
|
244,467
shares issuable upon the exercise of options;
|
|
•
|
368,572
shares of our common stock issuable upon conversion of senior convertible debentures;
|
|
•
|
164,867
shares of our common stock issuable upon conversion of shares of our Series D Convertible
Preferred Stock that are issuable upon exercise of preferred stock warrants;
|
|
•
|
2,916,667
shares of common stock that are issuable upon the exercise of common stock warrants issued
in the June Private Placement;
|
|
•
|
416,667
shares of common stock that are issuable upon the exercise of placement agent warrants
issued in the June Private Placement;
|
|
•
|
214,286
shares of our common stock issuable upon conversion of shares of our Series C Convertible
Preferred Stock issued in the June Private Placement, assuming a conversion price floor
of $0.35 per share; and
|
|
•
|
71,214,286
shares of our common stock issuable upon conversion of shares of our Series C Convertible
Preferred Stock that are issuable upon exercise of preferred stock warrants issued in
the June Private Placement, assuming a conversion price floor of $0.35 per share.
|
Unless otherwise
indicated, all information in this prospectus assumes no exercise of the outstanding options and warrants, and no conversion of
the outstanding convertible debentures and convertible preferred stock.
RISK FACTORS
An investment in our
securities involves significant risks. You should carefully consider and evaluate all of the information included and incorporated
by reference in this prospectus, including the risk factors described below with respect to our Series C Convertible Preferred
Stock, as well as the other risk factors incorporated herein by reference from “Item 1A. Risk Factors” of our Annual
Report on Form 10-K for the year ended December 31, 2016, which was filed with the SEC on March 31, 2017, and as further updated
by our subsequent Exchange Act filings we file with the SEC after the filing of the registration statement of which this prospectus
is a part and that are, in each case, incorporated by reference herein. Any of these risks could materially and adversely affect
our business, results of operations and financial condition, which in turn could materially and adversely affect the price of
our common stock and the value of your investment in our securities.
Risks Relating to the Series C Convertible
Preferred Stock
There is not currently and there
may never be an active trading market for our Series C Convertible Preferred Stock.
There currently is
no trading market for the Series C Convertible Preferred Stock and such a market may never develop. We have no plans to list the
Series C Convertible Preferred Stock on any national securities exchange.
We may not be able to raise the funds
necessary to redeem the Series C Convertible Preferred Stock if required to do so.
Under certain circumstances,
holders of the Series C Convertible Preferred Stock have the right to demand that we redeem Series C Convertible Preferred Stock.
If we are not able to raise the funds necessary to redeem such shares, we will not be able to comply with our redemption obligations
and holders of the Series C Convertible Preferred Stock will not be able to redeem their shares.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS
This prospectus (including
any documents incorporated by reference herein) contains statements with respect to us which constitute ‘‘forward-looking
statements’’ within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, and are intended to be covered by the ‘‘safe harbor’’ created by those
sections. Forward-looking statements, which are based on certain assumptions and reflect our plans, estimates and beliefs, can
generally be identified by the use of forward-looking terms such as “believes,” “expects,” “may,”
“will,” “should,” “could,” “seek,” “intends,” “plans,”
“estimates,” “anticipates” or other comparable terms. These forward looking statements include, but are
not limited to, statements concerning future events, our future financial performance, business strategy and plans and objectives
of management for future operations. Our actual results could differ materially from those discussed in the forward-looking statements.
Factors that could cause or contribute to these differences include those discussed in “Risk Factors” in the documents
incorporated by reference herein.
We caution readers not
to place undue reliance upon any such forward-looking statements, which speak only as of the date they are made. We disclaim any
obligation, except as specifically required by law and the rules of the Securities and Exchange Commission, to publicly update
or revise any such statements to reflect any change in company expectations or in events, conditions or circumstances on which
any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the
forward-looking statements.
You should read this prospectus
and the documents that we incorporate by reference herein and have filed as exhibits to the registration statement, of which this
prospectus is part, completely and with the understanding that our actual future results may be materially different from what
we expect. You should assume that the information appearing in this prospectus is accurate as of the date on the cover of this
prospectus only. Our business, financial condition, results of operations and prospects may change. We may not update these forward-looking
statements, even though our situation may change in the future, unless we have obligations under the federal securities laws to
update and disclose material developments related to previously disclosed information. We qualify all of the information presented
in this prospectus, and particularly our forward-looking statements, by these cautionary statements.
USE OF PROCEEDS
We are filing the registration
statement of which this prospectus is a part to permit holders of the shares of our Series C Convertible Preferred Stock, common
stock warrants, placement agent warrants and preferred stock warrants described in the section entitled “Selling Stockholders”
to resell such shares of our Series C Convertible Preferred Stock and common stock issuable upon the conversion of our Series
C Convertible Preferred Stock, shares of our common stock issuable upon the exercise of the common stock warrants and placement
agent warrants, and shares of our Series C Convertible Preferred Stock issuable upon the exercise of the preferred stock warrants
(and shares of our common stock that are issuable upon the conversion of the Series C Convertible Preferred Stock that are issuable
upon the exercise of the preferred stock warrants). We will not receive any proceeds from the resale of any shares of common stock
or Series C Convertible Preferred Stock offered by this prospectus by the selling stockholders. Upon the exercise of the common
stock warrants for 2,916,667 shares of our common stock by payment of cash, we will receive the exercise price of the warrants,
which is $3.00 per share, or an aggregate of approximately $8,750,001. Upon the exercise of the placement agent warrants for 416,667
shares of our common stock by payment of cash, we will receive the exercise price of the warrants, which is $3.30 per share, or
an aggregate of approximately $1,375,001. Upon the exercise of the preferred stock warrants for 24,925 shares of our Series C
Convertible Preferred Stock by payment of cash, we will receive the exercise price of the warrants, which is $900 per share, or
an aggregate of approximately $22,432,500.
The common stock warrants,
placement agent warrants and preferred stock warrants will not, upon the effectiveness (and continued effectiveness) of the registration
statement of which this prospectus is a part, be eligible for cashless-exercise treatment. We plan to use any cash received from
the exercise of the common stock warrants, placement agent warrants and preferred stock warrants for general corporate purposes.
General corporate purposes may include providing working capital, funding capital expenditures, or paying for acquisitions. We
currently do not have any arrangements or agreements for any acquisitions. We cannot precisely estimate the allocation of the
proceeds from any exercise of the warrants for cash. Accordingly, in the event the warrants are exercised for cash, our management
will have broad discretion in the application of the proceeds of such exercises. Pending the use of proceeds, we intend to invest
the proceeds of any warrant for cash exercise in certificates of deposit or direct or guaranteed obligations of the U.S. government.
There is no assurance that the warrants will ever be exercised for cash.
The selling stockholders
will pay any underwriting discounts and commissions and expenses incurred by such selling stockholders for brokerage, accounting,
tax or legal services or any other expenses incurred by such selling stockholders in disposing of the shares. We will bear all
other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus, including, without
limitation, all registration and filing fees, NASDAQ Capital Market listing fees and fees and expenses of our counsel and our auditors.
SELLING STOCKHOLDERS
The shares of preferred
stock being offered by the selling stockholders are those previously issued to the selling stockholders and those issuable to
the selling stockholders upon exercise of the preferred warrants. The shares of common stock being offered by the selling stockholders
are those issuable to the selling stockholders upon conversion of the preferred stock and exercise of the common stock warrants
and placement agent warrants. We are registering the shares of preferred stock and shares of common stock in order to permit the
selling stockholders to offer the shares for resale from time to time. Except for the ownership of our securities issued in the
June Private Placement and the July Registered Direct Offering, the selling stockholders have not had any material relationship
with us within the past three years other than Maxim Group LLC and its designees, which served as the placement agent for the
June Private Placement and received the placement agent warrants as consideration for services rendered. Maxim Group LLC is registered
under the Exchange Act as a broker-dealer. Other than Maxim Group LLC, to our knowledge, none of the selling stockholders listed
below are broker-dealers or affiliates of broker-dealers.
The first table below
lists the selling stockholders and other information regarding the beneficial ownership (as determined under Section 13(d) of
the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder) of the shares of preferred stock held
by each of the selling stockholders. The second column lists the number of shares of preferred stock beneficially owned by the
selling stockholders, based on their respective ownership of preferred stock and preferred warrants, as of August 9, 2017, assuming
exercise of the preferred warrants held by each such selling stockholder on that date. The third column lists the shares of preferred
stock being offered by this prospectus by the selling stockholders. The fourth column assumes the sale of all of the shares offered
by the selling stockholders pursuant to this prospectus.
The second table below
lists the selling stockholders and other information regarding the beneficial ownership (as determined under Section 13(d) of
the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder) of the shares of common stock held
by each of the selling stockholders. The second column lists the number of shares of common stock beneficially owned by the selling
stockholders, based on their respective ownership of shares of common stock, preferred stock, common stock warrants and placement
agent warrants, as of August 9, 2017, assuming conversion of the preferred stock, exercise of the preferred warrants, exercise
of the common stock warrants and exercise of the placement agent warrants held by each such selling stockholder on that date but
taking account of any limitations on conversion and exercise set forth therein. The third column lists the shares of common stock
being offered by this prospectus by the selling stockholders and does not take in account any limitations on (i) conversion of
the preferred stock set forth in the certificate of designations or (ii) exercise of the warrants set forth therein. The fourth
column assumes the sale of all of the shares offered by the selling stockholders pursuant to this prospectus.
Because the conversion
price of the preferred stock and the exercise price of the warrants may be adjusted, the number of shares that will actually be
issued may be more or less than the number of shares being offered by this prospectus.
Under the terms of
the preferred stock, common stock warrants and the placement agent warrants, a selling stockholder may not convert the preferred
stock or exercise the common stock warrants or placement agent warrants to the extent (but only to the extent) such selling stockholder
or any of its affiliates would beneficially own a number of shares of our common stock which would exceed 4.99% of the outstanding
shares of the Company. The number of shares in the second column reflects these limitations. The selling stockholders may sell
all, some or none of their shares in this offering. See “Plan of Distribution.”
Name of Selling Stockholder
|
|
Number of Shares of
Preferred Stock Owned
Prior to Offering
|
|
|
Maximum Number of
Shares
of Preferred Stock to be Sold
Pursuant to this Prospectus
|
|
|
Number of Shares of
Preferred Stock of
Owned After Offering
|
|
|
|
|
|
|
|
|
|
|
|
Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (1)
|
|
189,867
|
|
|
|
25,000
|
|
|
|
164,867
|
|
|
(1) Includes (i) 75 shares of Series C Convertible Preferred Stock issued and outstanding, (ii) 24,925 shares of Series C Convertible Preferred
Stock issuable upon exercise of outstanding Series C Preferred Stock Warrants and (iii) 164,867 shares of Series D Convertible
Preferred Stock issuable upon exercise of outstanding Series D Preferred Stock Warrants. An aggregate of 25,000 shares of
Series C Convertible Preferred Stock are being registered for resale pursuant to this prospectus. Ayrton Capital LLC, the investment manager
to Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, has discretionary authority to vote and dispose of the shares
held by Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B and may be deemed to be the beneficial owner of these
shares. Waqas Khatri, in his capacity as Managing Member of Ayrton Capital LLC, may also be deemed to have investment discretion
and voting power over the shares held by Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B. Alto Opportunity Master
Fund, SPC - Segregated Master Portfolio B and Mr. Khatri each disclaim any beneficial ownership of these shares. The address of
Ayrton Capital LLC is 1180 Avenue of the Americas, Suite 842, New York, NY 10036.
Name of Selling Stockholder
|
|
Number of Shares of
Common Stock Owned
Prior to Offering
|
|
|
Maximum Number of
Shares
of Common Stock to be Sold
Pursuant to this Prospectus
|
|
|
Number of Shares of
Common Stock of
Owned After Offering
|
|
|
|
|
|
|
|
|
|
|
|
Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (1)
|
|
|
597,473
|
|
|
|
74,345,239
|
|
|
|
471,522
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maxim Partners LLC (2)
|
|
|
416,667
|
|
|
|
416,667
|
|
|
|
0
|
|
(1) Under the
terms of the Common Stock Warrants, the holders do not have the right to exercise the warrants to the extent that after
giving effect to such exercise, the holder (together with its affiliates) would beneficially own in excess of 4.99% (the
‌Maximum Percentageâ€) of the shares of our common stock outstanding immediately after giving
effect to such exercise. Under the terms of the Series C Convertible Preferred Stock, the holders do not have the right to
convert the Series C Convertible Preferred Stock to the extent that after giving effect to such conversion, the
holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage. Under the terms of the
Series D Convertible Preferred Stock, the holders do not have the right to convert the Series D Convertible Preferred Stock
to the extent that after giving effect to such conversion, the holder (together with its affiliates) would beneficially own
in excess of the Maximum Percentage. The number of shares of common stock beneficially owned prior to the offering represents
the maximum number of shares of common stock beneficially owned after giving effect to the Maximum Percentage. The aggregate
number of shares owned prior to the offering, without giving effect to the Maximum Percentage, would equal 74,816,761 shares
of common stock as follows: (i) 473 shares of common stock issued and outstanding, (ii) 71,428,572 shares of common stock
issuable upon conversion of shares of Series C Convertible Preferred Stock assuming a conversion price equal to the
applicable floor price of $0.35 per share, (iii) 2,916,667 shares of common stock issuable upon exercise of outstanding
Common Stock Warrants and (iv) 471,049 shares of common stock issuable upon conversion of shares of Series D Convertible
Preferred Stock assuming a conversion price equal to the applicable floor price of $0.35 per share. An aggregate of
74,345,239 shares of common stock, representing the shares of common stock issuable upon conversion of shares of Series C
Convertible Preferred Stock and the shares of common stock issuable upon exercise of the Common Stock Warrants, are being
registered for resale pursuant to this prospectus. Ayrton Capital LLC, the investment manager to Alto Opportunity Master
Fund, SPC - Segregated Master Portfolio B, has discretionary authority to vote and dispose of the shares held by Alto
Opportunity Master Fund, SPC - Segregated Master Portfolio B and may be deemed to be the beneficial owner of these shares.
Waqas Khatri, in his capacity as Managing Member of Ayrton Capital LLC, may also be deemed to have investment discretion and
voting power over the shares held by Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B. Alto Opportunity
Master Fund, SPC - Segregated Master Portfolio B and Mr. Khatri each disclaim any beneficial ownership of these shares. The
address of Ayrton Capital LLC is 1180 Avenue of the Americas, Suite 842, New York, NY 10036.
(2) Includes 416,667
shares of common stock issuable upon the exercise of placement agent warrants. Maxim Partners LLC is an affiliate of Maxim Group,
LLC, a registered broker dealer and the placement agent in the June Private Placement. Michael Rabinowitz has discretionary authority
to vote and dispose of the shares of common stock held by Maxim Partners LLC and may be deemed to be the beneficial owner of these
shares. Maxim Partners LLC did not acquire the warrants in the ordinary course of its business; rather its affiliate, Maxim Group
LLC, acquired the warrants through its participation as placement agent in the June Private Placement.
DESCRIPTION OF SERIES
C CONVERTIBLE PREFERRED STOCK
The terms of the Series
C Convertible Preferred Stock, or the Series C Preferred Stock, are contained in the Certificate of Designations, Preferences
and Rights of the Series C Convertible Preferred Stock of MagneGas Corporation, or the Series C Certificate of Designations, that
we filed with the Secretary of State of the State of Delaware on June 15, 2017. The following description is a summary of
the material provisions of the Series C Preferred Stock and the Series C Certificate of Designations. It does not purport to be
complete and is qualified in all respects by the terms of the Series C Certificate of Designations. We urge you to read the Series
C Certificate of Designations because it, and not this description, defines the rights of holders of Series C Preferred Stock.
We have included the Series C Certificate of Designations in our Current Report on Form 8-K filed with the Commission on June
19, 2017 which is incorporated by reference into this prospectus.
Rank
The Series C Preferred
Stock, with respect to rights, powers, preferences and privileges, rank senior with respect to all shares of capital stock of
the Company, except for our Series A Preferred Stock, which rank pari passu to the Series C Preferred Stock, and unless holders
of at least a majority of the outstanding Series C Preferred Stock and Series A Preferred Stock, voting together as a single class,
consent to the creation of other capital stock of the Company that is senior or equal in rank to the Series C Preferred Stock
and Series A Preferred Stock.
Dividends
Holders of the Series
C Preferred Stock will be entitled to receive dividends, if and when declared by our Board of Directors, from time to time, in
its sole discretion and in accordance with the requirements of Delaware General Corporation Law. Upon the occurrence of certain
triggering events, the holders will be entitled to receive dividends at a rate of eighteen percent (18.0%) per annum.
Conversion
The shares of Series
C Preferred Stock are convertible into common stock at an initial conversion price of $3.00 per share, or the conversion price,
subject to certain adjustments. The Series C Preferred Stock may be converted into common stock at any time at the option of the
holders, subject to the limitations on beneficial ownership contained in the Series C Certificate of Designations.
On each applicable
installment date, provided there has been no equity conditions failure, we shall convert the applicable amount of Series C Preferred
Stock from each holder into shares of common stock; provided, however, that we may, at our option following notice to each holder,
redeem such amount of Series C Preferred Stock by paying to each holder the corresponding installment amount in cash.
The applicable installment
conversion price with respect to a particular date of determination, shall be equal to the lower of:
|
-
|
the conversion
price then in effect; and
|
|
-
|
the greater
of (a) $0.35 and (b) the lower of (i) 85% of the VWAP of the common stock as of the trading
day immediately preceding the applicable installment date and (ii) 85% of the quotient
of (A) the sum of the VWAP of the common stock for each of the ten (10) trading days
with the lowest VWAP of the common stock during the twenty (20) consecutive trading day
period ending and including the trading day immediately prior to the applicable installment
date, divided by (B) ten (10).
|
In addition, upon the
occurrence certain triggering events, a holder of Series C Preferred Stock has the option to convert a portion of the Series C
Preferred Stock into common stock at an alternate conversion price, which shall be the lower of:
|
-
|
the then-applicable
conversion price; and
|
|
-
|
the greater
of (a) $0.35 and (b) the lowest of (i) 85% of the VWAP of the common stock as of the
trading day immediately preceding the delivery or deemed delivery of the applicable conversion
notice, (ii) 85% of the VWAP of the common stock as of the trading day of the delivery
or deemed delivery of the applicable conversion notice and (iii) 85% of the price computed
as the quotient of (A) the sum of the VWAP of the common stock for each of the ten (10)
trading days with the lowest VWAP of the common stock during the twenty (20) consecutive
trading day period ending and including the trading day immediately preceding the delivery
or deemed delivery of the applicable conversion notice, divided by (B) ten (10).
|
Adjustment of Conversion Price
If and whenever we
subdivide or combine (by any stock split, stock dividend, stock combination, recapitalization or other similar transaction) our
outstanding common stock into a greater or smaller number of shares, then the conversion price in effect immediately prior to
such subdivision will be proportionately reduced or increased, as applicable.
Additionally, if and
whenever we issue or sell, or are deemed to have issued or sold, any shares of common stock (including the issuance or sale of
shares of common stock owned or held by or for our account, but excluding any excluded securities issued or sold or deemed to
have been issued or sold) for a consideration per share less than a price equal to the conversion price in effect immediately
prior to such issuance or sale or deemed issuance or sale then, immediately after such issuance, the conversion price then in
effect shall be reduced to an amount equal to the lower price.
Triggering Events
The Series C Certificate
of Designations provide for certain triggering events which include, but are not limited to:
|
(i)
|
our failure
to timely file a registration statement,
|
|
(ii)
|
the lapsing
of a registration statement that is required to remain effective,
|
|
(iii)
|
our suspension
(or threatened suspension) from trading or the failure (or threatened failure) of our
common stock to be trading or listed (as applicable) on an eligible market for a period
of five (5) consecutive trading days,
|
|
(iv)
|
notice to
any holder of Series C Preferred Stock or Series C Preferred Warrants of our intention
not to comply, as required, with a request for exercise of any warrants for warrant shares
in accordance with the provisions of the Series C Preferred Warrants or a request for
conversion of any Series C Preferred Stock into shares of common stock that is requested
in accordance with the provisions of the Series C Certificate of Designations,
|
|
(v)
|
the failure
to cure a conversion or delivery failure with five (5) trading days after the applicable
exercise or conversion date,
|
|
(vi)
|
failure to
maintain the authorized share allocation,
|
|
(vii)
|
failure
to reserve 100% of the aggregate number of additional Series C Preferred Stock as necessary
to effect the exercise in full of the Series C Preferred Warrants then outstanding,
|
|
(viii)
|
failure
of our Board of Directors to declare a dividend that’s required under the Series
C Certificate of Designations,
|
|
(ix)
|
our failure
to pay any amount when due,
|
|
(x)
|
our failure
to remove a restrictive legend when required to do so in conformity with applicable federal
law,
|
|
(xi)
|
the occurrence
of any default under, redemption of or acceleration prior to maturity of at least an
aggregate of $50,000 of indebtedness,
|
|
(xii)
|
bankruptcy
or insolvency or reorganization of the Company not dismissed within thirty (30) days
of initiation,
|
|
(xiii)
|
the entry
by a court of a decree, order, judgment or other similar document in respect of the Company
or any of our subsidiaries of a voluntary or involuntary case or proceeding under any
applicable federal, state or foreign bankruptcy, insolvency, reorganization or other
similar law,
|
|
(xiv)
|
under certain
circumstances, our becoming subject to judgments for the payment of money or defaulting
on indebtedness,
|
|
(xv)
|
our breach
of any transaction document,
|
|
(xvi)
|
any breach
of the Series C Certificate of Designations,
|
|
(xvii)
|
upon the
occurrence of certain material adverse events,
|
|
(xviii)
|
if any
provision of any transaction document ceases to be valid or enforceable, and
|
|
(xix)
|
if either
Ermanno Santilli or Scott Mahoney cease to be active officers and employees of the Company.
|
Redemption
In lieu of conversion,
upon the occurrence of certain triggering events, a holder may require that we redeem all or any of the Series C Preferred Stock
at a price equal to the greater of:
|
-
|
the product
of (a) the conversion amount of the Series C Preferred Stock to be redeemed multiplied
by (b) a redemption premium of 115%; and
|
|
-
|
the product
of (a) the conversion rate with respect to the conversion amount in effect at such time
of redemption multiplied by (b) the product of (i) a redemption premium of 115% multiplied
by (ii) the greatest closing sale price of the common stock on any trading day during
the period commencing on the date immediately preceding such triggering event and ending
on the date we make the entire redemption payment.
|
If we elect to effect
an installment redemption in lieu of an installment conversion, in whole or in part, such Series C Preferred Stock shall be redeemed
by us in cash on the applicable installment date in an amount equal to 103% of the applicable installment redemption amount.
In addition to the
redemptions described above, at any time no equity conditions failure exists, we shall have the right to redeem, in one redemption,
up to $10 million of the conversion amount of the Series C Preferred Stock then outstanding. The Series C Preferred Stock subject
to redemption at our option shall be redeemed by us in cash at a price equal to 115% of the greater of:
|
-
|
the conversion
amount of the Series C Preferred Stock being redeemed; and
|
|
-
|
the product
of (a) the conversion rate with respect to the conversion amount of the Series C Preferred
Stock being redeemed multiplied by (b) the greatest closing sale price of the common
stock on any trading day during the period commencing on the date immediately preceding
such redemption and ending on the trading day immediately prior to the date we make the
entire redemption payment.
|
Voting Rights
Holders of Series C
Preferred Stock shall have no voting rights, except as required by law (including without limitation, the Delaware General Corporation
Law) and as expressly provided in the Series C Certificate of Designations.
Exchange Listing
There is no established
public trading market for the Series C Preferred Stock, and we do not expect a market to develop. In addition, we do not intend
to apply for listing of the Series C Preferred Stock on any securities exchange or recognized trading system.
Limitations on Beneficial Ownership
The Series C Preferred
Stock may not be converted, and common stock may not be issued in connection therewith, if, after giving effect to the conversion
or issuance, a holder together with certain related parties would beneficially own in excess of 4.99% of the outstanding common
stock. At each holder's option, the cap may be raised or lowered to any other percentage not in excess of 9.99%, except that any
increase will only be effective upon 61-days' prior notice to us, and any increase or decrease will apply only to such holder.
DESCRIPTION
OF COMMON STOCK
General
Holders
of our common stock are entitled to one vote for each share on all matters submitted to a stockholder vote. Our common stock does
not have cumulative voting rights. Holders of our common stock representing a majority of the voting power of our capital stock
issued and outstanding and entitled to vote, represented in person or by proxy, are necessary to constitute a quorum at any meeting
of our stockholders. A vote by the holders of a majority of our outstanding shares is required to effectuate certain fundamental
corporate changes such as liquidation, merger or an amendment to our certificate of incorporation. Although there are no provisions
in our charter or by-laws that may delay, defer or prevent a change in control, the board of directors is authorized, without
stockholder approval, to issue shares of preferred stock that may contain rights or restrictions that could have this effect.
Holders of common stock are entitled to share in all dividends that the board of directors, in its discretion, declares from legally
available funds. In the event of liquidation, dissolution or winding up, each outstanding share entitles its holder to participate
pro rata in all assets that remain after payment of liabilities and after providing for each class of stock, if any, having preference
over the common stock. Holders of our common stock have no pre-emptive rights, no conversion rights and there are no redemption
provisions applicable to our common stock.
Election of
Directors
The
holders of shares of common stock and the equivalent shares of outstanding Series A Preferred Stock, voting together, shall appoint
the members of our board of directors. Each share of common stock is entitled to one vote.
Dividends
Since
inception we have not paid any dividends on our common stock. We currently do not anticipate paying any cash dividends in the
foreseeable future on our common stock. Although we intend to retain our earnings, if any, to finance the exploration and growth
of our business, our board of directors will have the discretion to declare and pay dividends in the future. Payment of dividends
in the future will depend upon our earnings, capital requirements, and other factors, which our board of directors may deem relevant.
Anti-Takeover
Effects of Provisions of the Delaware General Corporation Law and our Certificate of Incorporation and Bylaws
Provisions
of the Delaware General Corporation Law, or the DGCL, and our amended and restated certificate of incorporation and bylaws could
make it more difficult to acquire us by means of a tender offer, a proxy contest or otherwise, or to remove incumbent officers
and directors. These provisions, summarized below, are expected to discourage certain types of coercive takeover practices and
takeover bids that our board of directors may consider inadequate and to encourage persons seeking to acquire control of us to
first negotiate with our board of directors. We believe that the benefits of increased protection of our ability to negotiate
with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging
takeover or acquisition proposals because, among other things, negotiation of these proposals could result in improved terms for
our stockholders.
Delaware
Anti-Takeover Statute
. We are subject to Section 203 of the DGCL. Subject to certain exceptions, Section 203 prohibits a publicly
held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for
three years following the date the person became an interested stockholder, unless the interested stockholder attained such status
with the approval of our board of directors or unless the business combination is approved in a prescribed manner.
Section
203 of the DGCL generally defines a “business combination” to include, among other things, any merger or consolidation
involving us and the interested stockholder and the sale of more than 10% of our assets.
In
general, an “interested stockholder” is any entity or person beneficially owning 15% or more of our voting stock or
any entity or person associated or affiliated with or controlling or controlled by such entity or person.
Amendments
to Our Certificate of Incorporation
. Under the DGCL, the affirmative vote of a majority of the outstanding shares entitled
to vote thereon and a majority of the outstanding stock of each class entitled to vote thereon is required to amend a corporation’s
certificate of incorporation. Under the DGCL, the holders of the outstanding shares of a class of our capital stock shall be entitled
to vote as a class upon a proposed amendment, whether or not entitled to vote thereon by the certificate of incorporation, if
the amendment would:
|
-
|
increase or
decrease the aggregate number of authorized shares of such class;
|
|
-
|
increase or
decrease the par value of the shares of such class; or
|
|
-
|
alter or change
the powers, preferences or special rights of the shares of such class so as to affect
them adversely.
|
If
any proposed amendment would alter or change the powers, preferences or special rights of one or more series of any class of our
capital stock so as to affect them adversely, but shall not so affect the entire class, then only the shares of the series so
affected by the amendment shall be considered a separate class for the purposes of this provision.
Vacancies
in the board of directors
. Our bylaws provide that, subject to limitations, any vacancy occurring in our board of directors
for any reason may be filled by a majority of the remaining members of our board of directors then in office, even if such majority
is less than a quorum. Each director so elected shall hold office until the expiration of the term of the other directors. Each
such directors shall hold office until his or her successor is elected and qualified, or until the earlier of his or her death,
resignation or removal.
Special
Meetings of Stockholders
. Under our bylaws, special meetings of stockholders may be called at any time by our President whenever
so directed in writing by a majority of the entire board of directors. Special meetings can also be called whenever one-third
of the number of shares of our capital stock entitled to vote at such meeting shall, in writing, request one. Under the DGCL,
written notice of any special meeting must be given not less than 10 nor more than 60 days before the date of the special meeting
to each stockholder entitled to vote at such meeting.
No
Cumulative Voting
. The DGCL provides that stockholders are denied the right to cumulate votes in the election of directors
unless our certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation does not provide
for cumulative voting.
The NASDAQ
Capital Market Listing
Our
common stock is listed on the NASDAQ Capital Market under the symbol “MNGA.”
Transfer Agent
and Registrar
The
transfer agent and registrar for our common stock is Corporate Stock Transfer, Inc. The transfer agent’s address is 3200
Cherry Creek South Drive, Suite 430, Denver, CO 80209, and its telephone number is (303) 282-4800.
PLAN OF DISTRIBUTION
We are registering
the shares of preferred stock outstanding and issuable upon exercise of the preferred warrants and the shares of common stock
issuable upon conversion of the preferred stock and exercise of the common stock warrants and placement agent warrants to permit
the resale of these shares of preferred stock and common stock by the holders of the preferred stock, preferred warrants, common
stock warrants and placement agent warrants from time to time after the date of this prospectus. We will receive proceeds from
the exercise of any preferred warrants. We will not receive any of the proceeds from the sale by the selling stockholders of the
shares of common stock, although we will receive the exercise price of any common stock warrants or placement agent warrants not
exercised by the selling stockholders on a cashless exercise basis. We will bear all fees and expenses incident to our obligation
to register the shares of preferred stock and common stock.
The selling stockholders
may sell all or a portion of the shares of preferred stock and common stock held by them and offered hereby from time to time
directly or through one or more underwriters, broker-dealers or agents. If the shares of preferred stock or common stock are sold
through underwriters or broker-dealers, the selling stockholders will be responsible for underwriting discounts or commissions
or agent’s commissions. The shares of preferred stock and common stock may be sold in one or more transactions at fixed
prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale or at negotiated
prices. These sales may be effected in transactions, which may involve crosses or block transactions, pursuant to one or more
of the following methods:
• on
any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;
• in
the over-the-counter market;
• in
transactions otherwise than on these exchanges or systems or in the over-the-counter market;
• through
the writing or settlement of options, whether such options are listed on an options exchange or otherwise;
• ordinary
brokerage transactions and transactions in which the broker-dealer solicits purchasers;
• block
trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block
as principal to facilitate the transaction;
• purchases
by a broker-dealer as principal and resale by the broker-dealer for its account;
• an
exchange distribution in accordance with the rules of the applicable exchange;
• privately
negotiated transactions;
• short
sales made after the date the Registration Statement is declared effective by the SEC;
• broker-dealers
may agree with a selling security holder to sell a specified number of such shares at a stipulated price per share;
• a
combination of any such methods of sale; and
• any
other method permitted pursuant to applicable law.
The selling stockholders
may also sell shares of preferred stock and common stock under Rule 144 promulgated under the Securities Act of 1933, as amended,
if available, rather than under this prospectus. In addition, the selling stockholders may transfer the shares of preferred stock
and common stock by other means not described in this prospectus. If the selling stockholders effect such transactions by selling
shares of preferred stock or common stock to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers
or agents may receive commissions in the form of discounts, concessions or commissions from the selling stockholders or commissions
from purchasers of the shares of preferred stock or common stock for whom they may act as agent or to whom they may sell as principal
(which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess of those
customary in the types of transactions involved). In connection with sales of the shares of preferred stock or common stock or
otherwise, the selling stockholders may enter into hedging transactions with broker-dealers, which may in turn engage in short
sales of the shares of preferred stock or common stock in the course of hedging in positions they assume. The selling stockholders
may also sell shares of preferred stock or common stock short and deliver shares of preferred stock or common stock, as applicable,
covered by this prospectus to close out short positions and to return borrowed shares in connection with such short sales. The
selling stockholders may also loan or pledge shares of preferred stock or common stock to broker-dealers that in turn may sell
such shares.
The selling stockholders
may pledge or grant a security interest in some or all of the preferred stock, preferred warrants, common stock warrants, placement
agent warrants or shares of common stock owned by them and, if they default in the performance of their secured obligations, the
pledgees or secured parties may offer and sell the shares of preferred stock or common stock from time to time pursuant to this
prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending,
if necessary, the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders
under this prospectus. The selling stockholders also may transfer and donate the shares of preferred stock or common stock in
other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial
owners for purposes of this prospectus.
To the extent required
by the Securities Act and the rules and regulations thereunder, the selling stockholders and any broker-dealer participating in
the distribution of the shares of preferred stock or common stock may be deemed to be “underwriters” within the meaning
of the Securities Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed
to be underwriting commissions or discounts under the Securities Act. At the time a particular offering of the shares of preferred
stock or common stock is made, a prospectus supplement, if required, will be distributed, which will set forth the aggregate amount
of shares of common stock being offered and the terms of the offering, including the name or names of any broker-dealers or agents,
any discounts, commissions and other terms constituting compensation from the selling stockholders and any discounts, commissions
or concessions allowed or re-allowed or paid to broker-dealers.
Under the securities
laws of some states, the shares of preferred stock and common stock may be sold in such states only through registered or licensed
brokers or dealers. In addition, in some states the shares of preferred stock and common stock may not be sold unless such shares
have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is
complied with.
There can be no assurance
that any selling stockholder will sell any or all of the shares of preferred stock or common stock registered pursuant to the
registration statement, of which this prospectus forms a part.
The selling stockholders
and any other person participating in such distribution will be subject to applicable provisions of the Securities Exchange Act
of 1934, as amended, and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation
M of the Exchange Act, which may limit the timing of purchases and sales of any of the shares of preferred stock or common stock
by the selling stockholders and any other participating person. To the extent applicable, Regulation M may also restrict the ability
of any person engaged in the distribution of the shares of common stock to engage in market-making activities with respect to
the shares of preferred stock or common stock. All of the foregoing may affect the marketability of the shares of preferred stock
or common stock and the ability of any person or entity to engage in market-making activities with respect to the shares of preferred
stock or common stock.
We will pay all expenses
of the registration of the shares of preferred stock and common stock pursuant to the registration rights agreement, including,
without limitation, Securities and Exchange Commission filing fees and expenses of compliance with state securities or “blue
sky” laws; provided, however, a selling stockholder will pay all underwriting discounts and selling commissions, if any.
We will indemnify the selling stockholders against liabilities, including some liabilities under the Securities Act in accordance
with the registration rights agreements or the selling stockholders will be entitled to contribution. We may be indemnified by
the selling stockholders against civil liabilities, including liabilities under the Securities Act that may arise from any written
information furnished to us by the selling stockholder specifically for use in this prospectus, in accordance with the related
registration rights agreements or we may be entitled to contribution.
Once sold under the
registration statement, of which this prospectus forms a part, the shares of preferred stock and common stock will be freely tradable
in the hands of persons other than our affiliates.
LEGAL MATTERS
Certain legal matters with
respect to the securities will be passed upon for us by Goodwin Procter LLP, New York, New York.
EXPERTS
The consolidated financial
statements of MagneGas Corporation as of December 31, 2016 and for the year ended December 31, 2016 incorporated in this prospectus
by reference to our Annual Report on Form 10-K for the year ended December 31, 2016, have been so incorporated on reliance on the
report (which contains an explanatory paragraph relating to our ability to continue as a going concern as described in the notes
to the consolidated financial statements) of Marcum LLP, an independent registered public accounting firm, given on the authority
of said firm as experts in auditing and accounting.
The consolidated financial
statements of MagneGas Corporation as of December 31, 2015 and for the year ended December 31, 2015 incorporated in this prospectus
by reference to our Annual Report on Form 10-K for the year ended December 31, 2016, have been so incorporated on reliance on the
report of Stevenson & Company CPAS LLC, an independent registered public accounting firm, given on the authority of said firm
as experts in auditing and accounting.
WHERE YOU CAN FIND
MORE INFORMATION
This prospectus is part
of the registration statement on Form S-3 we filed with the SEC under the Securities Act of 1933, as amended, and does not contain
all the information set forth in the registration statement. Whenever a reference is made in this prospectus to any of our contracts,
agreements or other documents, the reference may not be complete, and you should refer to the exhibits that are a part of the registration
statement or the exhibits to the reports or other documents incorporated by reference in this prospectus for a copy of such contract,
agreement or other document.
Because we are subject
to the information and reporting requirements of the Securities Exchange Act of 1934, as amended, we file annual, quarterly and
special reports, and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC’s
website at http://www.sec.gov or on our website at http://www.magnegas.com.
The website addresses referenced
herein are not intended to function as hyperlinks, and the information contained in our website and in the SEC's website is not
incorporated by reference into this prospectus and should not be considered to be part of this prospectus.
In addition, the public
may read and copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F Street, N.E., Room 1580,
Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.
INFORMATION INCORPORATED BY REFERENCE
The SEC allows us to incorporate
by reference the information we file with it, which means that we can disclose important information to you by referring you to
those documents. Any statement contained in a document incorporated by reference herein shall be deemed to be modified or superseded
for purposes of this prospectus to the extent that a statement contained herein modifies or supersedes such statement. Any statement
so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. Any
information that we file with the SEC after the date of the initial registration statement of which this prospectus forms a part
and prior to effectiveness of the registration statement will automatically update and supersede the information contained in this
prospectus. This prospectus incorporates by reference our documents listed below and any future filings we make with the SEC under
Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act until all of the securities are sold:
|
·
|
Our
Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on March 31, 2017.
|
|
·
|
Our
Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, filed with the SEC on May 15, 2017.
|
|
·
|
Our
Current Reports on Form 8-K and Form 8-K/A, filed with the SEC on January 5, 2017, February
3, 2017, May 9, 2017, May 11, 2017, May 17, 2017, May 22, 2017, May 25, 2017, June 8,
2017, June 12, 2017, June 13, 2017, June 14, 2017, June 19, 2017, June 20, 2017 (Form
8-K/A only), June 21, 2017, July 24, 2017, July 25, 2017, July 26, 2017, July 27, 2017,
July 31, 2017, August 9, 2017 and August 14, 2017.
|
|
·
|
Our
definitive proxy statement on Schedule 14A filed with the SEC on April 21, 2017.
|
|
·
|
Our
definitive information statement on Schedule 14C filed with the SEC on June 7, 2017.
|
|
·
|
Our
definitive information statement on Schedule 14C filed with the SEC on July 3, 2017.
|
|
·
|
Our
definitive information statement on Schedule 14C filed with the SEC on July 24, 2017.
|
Notwithstanding the foregoing,
we are not incorporating any document or portion thereof or information deemed to have been furnished and not filed in accordance
with SEC rules.
You may request a free
copy of the above mentioned filings or any subsequent filings we incorporate by reference to this prospectus by writing or telephoning
us at the following address: MagneGas Corporation, 11885 44
th
Street North, Clearwater, FL 33762, (727) 934-3448.
PART II— INFORMATION NOT REQUIRED IN
THE PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution.
The following table sets forth the fees and
expenses payable by the Company in connection with the sale of the securities being registered hereby. All amounts shown are estimates
except the SEC registration fee. All of these fees and expenses will be borne by the Company.
Securities and Exchange Commission Registration Fee
|
|
$
|
3,385
|
|
Accounting Fees and Expenses
|
|
|
10,000
|
|
Legal Fees and Expenses
|
|
|
30,000
|
|
Miscellaneous Expenses
|
|
|
6,615
|
|
Total
|
|
$
|
50,000
|
|
Item 15. Indemnification of Directors and Officers.
The
Delaware General Corporation Law and our certificate of incorporation and by-laws provide for indemnification of our directors
and officers for liabilities and expenses that they may incur in such capacities. In general, directors and officers are indemnified
with respect to actions taken in good faith in a manner reasonably believed to be in, or not opposed to, the best interests of
the registrant and, with respect to any criminal action or proceeding, actions that the indemnitee had no reasonable cause to believe
were unlawful.
Our
certificate of incorporation provides that no director shall be personally liable to us or to our stockholders for monetary damages
for breach of fiduciary duty as a director, except that the limitation shall not eliminate or limit liability to the extent that
the elimination or limitation of such liability is not permitted by the Delaware General Corporation Law as the same exists or
may hereafter be amended.
Our
by-laws further provide for the indemnification of our directors and officers to the fullest extent permitted by Section 145 of
the Delaware General Corporation Law, including circumstances in which indemnification is otherwise discretionary. A principal
effect of these provisions is to limit or eliminate the potential liability of our directors for monetary damages arising from
breaches of their duty of care, subject to certain exceptions. These provisions may also shield directors from liability under
federal and state securities laws.
Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling
persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification
is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a
successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, we will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to the court of appropriate jurisdiction the question whether such indemnification by it is against public policy
as expressed in the Securities Act and will be governed by the final adjudication of such issue.
We
maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising
out of claims based on acts or omissions in their capacities as directors or officers.
Item 16. Exhibits
and Financial Statement Schedules.
The
exhibits to the registration statement for this offering are listed in the Exhibit Index attached hereto and incorporated by reference
herein.
|
(b)
|
Financial Statement Schedules.
|
No
financial statement schedules have been submitted because they are not required or are not applicable or because the information
required is included in the consolidated financial statements or the notes thereto.
Item 17. Undertakings.
|
(a)
|
The undersigned registrant hereby undertakes:
|
(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
i.
To include any prospectus required by section 10(a)(3) of the Securities Act;
ii.
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high
end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule
424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering
price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
iii.
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement.
Provided
however, that paragraphs (1)(i), (1)(ii) and (1)(iii) of this section do not apply if the information required to be included in
a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant
to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained
in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
(2)
That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at
the termination of the offering.
(4)
That, for the purpose of determining liability under the Securities Act to any purchaser:
(i)
each prospectus filed pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed
prospectus was deemed part of and included in the registration statement; and
(ii)
each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance
on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information
required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of
the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of
securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any
person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement
relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof; provided, however, that no statement made in a registration
statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by
reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with
a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement
or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.
(b)
The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing
of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing
of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference
in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c)
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion
of the SEC such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event
that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid
by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will,
unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final
adjudication of such issue.
SIGNATURES
Pursuant to the requirements
of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in the City of Clearwater, State of Florida, on August 14, 2017.
|
MAGNEGAS CORPORATION
|
|
|
|
|
By:
|
/s/ Ermanno Santilli
|
|
|
Ermanno Santilli
|
|
|
Chief Executive Officer
(Principal Executive Officer)
|
Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the
capacities held on the dates indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ ERMANNO
SANTILLI
|
|
Chief Executive
Officer and Director
|
|
August 14, 2017
|
Ermanno
Santilli
|
|
(Principal
Executive Officer)
|
|
|
|
|
|
|
|
/s/ SCOTT
MAHONEY
|
|
Chief Financial
Officer and Secretary
|
|
August 14, 2017
|
Scott
Mahoney
|
|
(Principal
Financial and Accounting Officer)
|
|
|
|
|
|
|
|
*
|
|
|
|
|
Robert
Dingess
|
|
Director
|
|
August 14, 2017
|
|
|
|
|
|
*
|
|
|
|
|
Luisa
Ingargiola
|
|
Director
|
|
August 14, 2017
|
|
|
|
|
|
*
|
|
|
|
|
Carla
Santilli
|
|
Director
|
|
August 14, 2017
|
|
|
|
|
|
*
|
|
|
|
|
Kevin
Pollack
|
|
Director
|
|
August 14, 2017
|
|
|
|
|
|
*
|
|
|
|
|
William
Staunton
|
|
Director
|
|
August 14, 2017
|
|
|
|
|
|
*
|
|
|
|
|
Joe
Stone
|
|
Director
|
|
August 14, 2017
|
|
|
|
|
|
*
|
|
|
|
|
Christopher
Huntington
|
|
Director
|
|
August 14, 2017
|
* By:
|
/s/
SCOTT MAHONEY
|
|
|
Scott Mahoney
|
|
|
Attorney-in-fact
|
|
EXHIBIT INDEX
Exhibit
Number
|
|
Description
|
|
|
|
3.1
|
|
Amended and Restated Certificate of Incorporation of MagneGas Corporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 19, 2017).
|
3.2
|
|
Certificate of Designations for Series C Convertible Preferred Stock of MagneGas Corporation (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on June 19, 2017).
|
3.3
|
|
Certificate of Designations for Series D
Convertible Preferred Stock of MagneGas Corporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current
Report on Form 8-K filed on July 27, 2017).
|
3.4
|
|
Bylaws of MagneGas Corporation (incorporated
by reference to Exhibit 3.2 to the Registrant’s Registration Statement on Form 10SB filed on April 3, 2006).
|
3.5
|
|
Amendment No. 1 to Bylaws of MagneGas Corporation
(incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on September 29, 2016).
|
4.1
|
|
Form of Warrant to Purchase Series C Convertible Preferred Stock of MagneGas Corporation (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on June 12, 2017).
|
4.2
|
|
Form of Warrant to Purchase Common Stock of MagneGas Corporation (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed on June 12, 2017).
|
4.3
|
|
Form of Placement Agent Warrant of MagneGas Corporation (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on June 19, 2017).
|
5.1
|
|
Opinion of Goodwin Procter LLP.
|
10.1
|
|
Securities Purchase Agreement dated June 12, 2017, by and among MagneGas Corporation and the buyers identified on the signature pages thereto (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on June 12, 2017).
|
10.2
|
|
Form of Registration Rights Agreement by and among MagneGas Corporation and the buyers identified on the signature pages thereto (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed on June 12, 2017).
|
10.3
|
|
Amended and Restated Registration Rights
Agreement by and among MagneGas Corporation and the buyers identified on the signature pages thereto (incorporated by reference
to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on August 14, 2017).
|
21.1
|
|
List of Subsidiaries (Previously filed)
|
23.1
|
|
Consent of Marcum LLP, an independent registered public accounting firm.
|
23.2
|
|
Consent of Stevenson & Company CPAS LLC, an independent registered public accounting firm.
|
23.3
|
|
Consent of Goodwin Procter LLP (included in the opinion filed as Exhibit 5.1)
|
24.1
|
|
Power of Attorney ( Previously filed).
|
Magnegas Applied Technlgy Sol (MM) (NASDAQ:MNGA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Magnegas Applied Technlgy Sol (MM) (NASDAQ:MNGA)
Historical Stock Chart
From Apr 2023 to Apr 2024